SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Rothenberg Mace L)
 

Sökning: WFRF:(Rothenberg Mace L) > (2008) > Potential regional ...

  • Haller, Daniel G (författare)

Potential regional differences for the tolerability profiles of fluoropyrimidines.

  • Artikel/kapitelEngelska2008

Förlag, utgivningsår, omfång ...

  • 2008

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/75176
  • https://gup.ub.gu.se/publication/75176URI
  • https://doi.org/10.1200/JCO.2007.15.2090DOI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: We conducted a retrospective analysis of safety data from randomized, single-agent fluoropyrimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to test the hypothesis that there are regional differences in fluoropyrimidine tolerability. METHODS: Treatment-related safety data from three phase III clinical studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing capecitabine plus oxaliplatin (XELOX) with bolus FU/LV as adjuvant treatment for colon cancer. The United States (US) was compared with non-US countries (all three studies) and with the rest of the world and East Asia (adjuvant study). RESULTS: In the MCRC studies (n = 1,189), more grade 3/4 adverse events (AEs; relative risk [RR], 1.77), dose reductions (RR, 1.72), and discontinuations (RR, 1.83) were reported in US versus non-US patients. Likewise, in the adjuvant colon cancer study (n = 1,864), more grade 3/4 AEs (RR, 1.47) and discontinuations (RR, 2.09) were reported in US versus non-US patients. After further dividing non-US patients into those in East Asia and the rest of the world, differential RRs for related grade 3/4 AEs, grade 4 AEs, and serious AEs were again observed, with East Asian patients having the lowest and US patients the highest RR. CONCLUSION: Regional differences exist in the tolerability profiles of fluoropyrimidines. More treatment-related toxicity was reported in the US compared with the rest of the world for bolus FU/LV and capecitabine in first-line MCRC and adjuvant colon cancer. In the adjuvant setting, a range of fluoropyrimidine tolerability was observed, with East Asian patients having the lowest, and US patients the highest, RR.

Ämnesord och genrebeteckningar

  • MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kirurgi hsv//swe
  • MEDICAL AND HEALTH SCIENCES Clinical Medicine Surgery hsv//eng
  • Antimetabolites
  • Antineoplastic
  • administration & dosage
  • adverse effects
  • Antineoplastic Combined Chemotherapy Protocols
  • adverse effects
  • Chemotherapy
  • Adjuvant
  • Colorectal Neoplasms
  • drug therapy
  • ethnology
  • pathology
  • Deoxycytidine
  • administration & dosage
  • adverse effects
  • analogs & derivatives
  • Europe
  • Far East
  • Fluorouracil
  • administration & dosage
  • adverse effects
  • analogs & derivatives
  • Gastrointestinal Diseases
  • chemically induced
  • ethnology
  • Humans
  • Leucovorin
  • administration & dosage
  • Neoplasm Metastasis
  • Neutropenia
  • chemically induced
  • ethnology
  • Organoplatinum Compounds
  • administration & dosage
  • Prodrugs
  • administration & dosage
  • adverse effects
  • Residence Characteristics
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome
  • United States
  • Vitamin B Complex
  • administration & dosage
  • Withholding Treatment

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Cassidy, Jim (författare)
  • Clarke, Stephen J (författare)
  • Cunningham, David (författare)
  • Van Cutsem, Eric (författare)
  • Hoff, Paulo M (författare)
  • Rothenberg, Mace L (författare)
  • Saltz, Leonard B (författare)
  • Schmoll, Hans-Joachim (författare)
  • Allegra, Carmen (författare)
  • Bertino, Joseph R (författare)
  • Douillard, Jean-Yves (författare)
  • Gustavsson, Bengt,1947Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xguben (författare)
  • Milano, Gerard (författare)
  • O'Connell, Michael (författare)
  • Rustum, Youcef (författare)
  • Tabernero, Josep (författare)
  • Gilberg, Frank (författare)
  • Sirzén, Florin (författare)
  • Twelves, Chris (författare)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of clinical oncology : official journal of the American Society of Clinical Oncology26:13, s. 2118-231527-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy